Pancreatic cancer (PC) is one of the most lethal cancers worldwide. Recently, fatty pancreas (FP) has been studied thoroughly, and although its relationship to PC is not fully understood, FP is suspected to contribute to the development of PC. We aimed to assess the association between PC and FP by conducting a systematic review and meta-analysis. We systematically searched three databases, MEDLINE, Embase, and CENTRAL, on 21 October 2022. Case–control and cross-sectional studies reporting on patients where the intra-pancreatic fat deposition was determined by modern radiology or histology were included. As main outcome parameters, FP in patients with and without PC and PC in patients with and without FP were measured. Proportion and odds ratio (OR) with a 95% confidence interval (CI) were used for effect size measure. PC among patients with FP was 32% (OR 1.32; 95% CI 0.42–4.16). However, the probability of having FP among patients with PC was more than six times higher (OR 6.13; 95% CI 2.61–14.42) than in patients without PC, whereas the proportion of FP among patients with PC was 0.62 (95% CI 0.42–0.79). Patients identified with FP are at risk of developing PC. Proper screening and follow-up of patients with FP may be recommended.
胰腺癌是全球范围内致死率最高的恶性肿瘤之一。近年来，脂肪胰受到广泛研究，尽管其与胰腺癌的关联机制尚未完全阐明，但脂肪胰被认为可能促进胰腺癌的发生发展。本研究旨在通过系统综述与荟萃分析评估胰腺癌与脂肪胰之间的关联性。我们于2022年10月21日系统检索了MEDLINE、Embase和CENTRAL三大数据库，纳入通过现代影像学或组织学方法测定胰腺内脂肪沉积的病例对照研究及横断面研究。主要结局指标包括：胰腺癌患者与非胰腺癌患者的脂肪胰患病情况，以及脂肪胰患者与非脂肪胰患者的胰腺癌患病情况。采用比例值及比值比（OR）作为效应量指标，并计算95%置信区间（CI）。脂肪胰患者中胰腺癌的患病率为32%（OR 1.32；95% CI 0.42-4.16）。值得注意的是，胰腺癌患者罹患脂肪胰的概率是非胰腺癌患者的六倍以上（OR 6.13；95% CI 2.61-14.42），而胰腺癌患者中脂肪胰的患病比例为0.62（95% CI 0.42-0.79）。研究结果表明，脂肪胰患者存在发展为胰腺癌的风险。建议对脂肪胰患者进行规范筛查与定期随访。
肿瘤(癌症)患者之家